This list is an analysis based on recent market events. It's not an investment recommendation.
About
Aptahem AB (publ), a biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in pre-clinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various consultants and contract research laboratories, including The Nencki Institute of Experimental Biology, BioSpring, Red Glead Discovery, SmiLe Incubator, Truly Translational Sweden AB, Axolabs, Accelera, PKxpert AB, Hooke Laboratories; Cardiovascular Research Centre; and Ã-rebro University. Aptahem AB (publ) was founded in 2014 and is based in Malmö, Sweden.
The current price of 94V.STU is €0.10 EUR — it has increased by +0% in the past 24 hours. Watch Aptahem AB stock price performance more closely on the chart.
What is Aptahem AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Aptahem AB stocks are traded under the ticker 94V.STU.
What is Aptahem AB market cap?▼
Today Aptahem AB has the market capitalization of 2.1M
What is Aptahem AB revenue for the last year?▼
Aptahem AB revenue for the last year amounts to 0 EUR.
What is Aptahem AB net income for the last year?▼
94V.STU net income for the last year is -592,795.24 EUR.
How many employees does Aptahem AB have?▼
As of November 2, 2026, the company has 6 employees.
In which sector is Aptahem AB located?▼
Aptahem AB operates in the Health & Wellness sector.
When did Aptahem AB complete a stock split?▼
The last stock split for Aptahem AB was on July 8, 2024 with a ratio of 1:100.